Business Of Biotech podkast

Managing Mergers With Sail Biomedicines' Guillaume Pfefer, Ph.D.

0:00
51:07
Do tyłu o 15 sekund
Do przodu o 15 sekund

We love to hear from our listeners. Send us a message.

While you might be aware that Sail Biomedicines  was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume  Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.  On this episode  of the Business of Biotech, Dr. Pfefer takes us under the hood of Sail Biomedicines and its mission to marry evolution and AI to develop programmable medicines based on eRNA.

You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Więcej odcinków z kanału "Business Of Biotech"